About Mand-peptide
Two decades of peptide manufacturing excellence. From a small Cambridge research lab to a global peptide manufacturing partner trusted by pharmaceutical and biotech leaders.
Pioneering Peptide Science Since 2005
Mand-peptide was founded with a singular mission: to make high-quality peptides accessible to researchers and pharmaceutical developers worldwide. What began as a small laboratory serving local academic institutions has grown into a global manufacturing operation.
Today, our 15,000 sq ft cGMP facility in Cambridge, Massachusetts produces hundreds of peptide compounds monthly, ranging from milligram research samples to multi-kilogram pharmaceutical batches. We serve clients across 40+ countries including major pharmaceutical companies, biotech startups, academic research centers, and cosmetic brands.
Our team of 80+ scientists, engineers, and quality professionals is united by a commitment to scientific excellence and customer success.
Our Core Values
The principles that guide every peptide we synthesize
Scientific Excellence
We approach every synthesis with rigorous scientific methodology, ensuring reproducible results and complete analytical transparency.
Customer Partnership
We view clients as long-term partners, providing technical consultation from project conception through commercial scale-up.
Regulatory Integrity
Unwavering commitment to regulatory compliance. Every batch meets or exceeds the strictest international pharmaceutical standards.
Innovation & R&D
Continuous investment in novel synthesis technologies, green chemistry methods, and next-generation peptide therapeutics.
Our Journey
Key milestones in Mand-peptide's growth story
Company Founded
Mand-peptide established in Cambridge, MA as a specialized peptide synthesis laboratory for academic research partners.
GMP Facility Launch
Opened first cGMP-compliant manufacturing facility with 2,000 sq ft cleanroom space and ISO 7 classification.
ISO 9001 Certification
Achieved ISO 9001:2008 quality management certification, expanding services to pharmaceutical clients.
European Market Entry
Obtained EMA cGMP certification and began supplying peptide APIs to European pharmaceutical manufacturers.
Capacity Expansion
Completed facility expansion to 15,000 sq ft with additional lyophilization suites and analytical labs.
ISO 13485 & Medical Devices
Achieved ISO 13485 certification and launched medical-grade peptide production for diagnostic applications.
Global Distribution Network
Established distribution partnerships across 40+ countries with temperature-controlled logistics.
Next-Gen Synthesis Platform
Deployed proprietary continuous-flow peptide synthesis technology, increasing throughput by 400%.
Leadership Team
Experienced scientists and business leaders driving peptide innovation
Dr. Sarah Chen
Chief Scientific Officer
Ph.D. Organic Chemistry, MIT. 25+ years in peptide synthesis and pharmaceutical development. Former Principal Scientist at Novartis.
Dr. Michael Torres
VP of Manufacturing
Ph.D. Chemical Engineering, Stanford. Led GMP facility design for 3 major pharma companies. Expert in continuous manufacturing.
Dr. Anna Volkov
Director of QC/QA
Ph.D. Analytical Chemistry, ETH Zurich. Former head of QC at Roche. Specialist in mass spectrometry and method validation.
James Wilson
VP Business Development
MBA, Harvard Business School. 15 years in biotech commercialization. Led market entry strategies for 20+ peptide products.